Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia

Inclusion criteria

• ✓. Failure to achieve CR after 2 cycles of standard chemotherapy;
• ✓. Initial induction achieved CR, but CR duration ≤12 months;
• ✓. Relapsed/refractory B-ALL refractory to first or multiple salvage therapies;
• ✓. Post-hematopoietic stem cell transplantation relapse, including hematological relapse and minimal residual disease (MRD) positivity;
• ✓. Patients for whom no standard therapy exists.